Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 14/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27924944 | 0.88 | SMN1; SMN2 (0.52) | P4HTMFFAR1LMNAL3MBTL1TBXAS1 | |
| SCHEMBL5296032 | 0.85 | MAPT (0.55) | TBXAS1 | |
| SCHEMBL25219823 | 0.79 | P4HTM (0.55) | P4HTMKEAP1FFAR1FFAR4TBXAS1 | |
| SCHEMBL7390689 | 0.79 | P4HTM (0.55) | P4HTMKEAP1FFAR1FFAR4TBXAS1 | |
| SCHEMBL25214681 | 0.79 | P4HTM (0.55) | P4HTMKEAP1FFAR1FFAR4LMNA | |
| SCHEMBL5521447 | 0.79 | P4HTM (0.50) | P4HTMKEAP1FFAR1NPSR1FFAR4 | |
| SCHEMBL9105603 | 0.79 | TSHR (0.43) | LMNA | |
| SCHEMBL990694 | 0.79 | TSHR (0.64) | P4HTMKEAP1FFAR1FFAR4LMNA | |
| SCHEMBL4426932 | 0.79 | P4HTM (0.50) | P4HTMKEAP1FFAR1FFAR4LMNA | |
| SCHEMBL7017455 | 0.78 | GABRP (0.52) | P4HTMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1173424-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066566-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | P4HTM 2230/4885KEAP1 1511/4885FFAR1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.